Apitope

Apitope is a clinical stage biotech company, established in 2002 and based in Belgium. The company focuses on developing potential first-in-class antigen-specific immunotherapeutics targeting the immunological basis of autoimmune diseases. Apitope uses a novel, proprietary discovery platform to select and develop highly specific peptide-based therapies, known as “apitopes®”, which restore the natural balance (immune tolerance) of the immune system, thus avoiding global immune suppression. The lead product candidate, ATX-MS-1467, shows promise in treating multiple sclerosis with high efficacy and a differentiating safety profile. Another lead product, ATX-GD-59, offers potential as the first disease-modifying treatment for Graves' disease.

Apitope's robust pipeline includes innovative, potential first-in-class product candidates in development for various indications such as uveitis, factor VIII inhibitors, myocarditis, and rheumatoid arthritis. The company secured a €12.00M Series B investment on 29 September 2015, with participation from Limburgse Reconversie Maatschappij, Vesalius Biocapital, Arthurian Life Sciences, PMV Pharmaceuticals, and Wyvern Seed Fund.

With an experienced leadership team, Apitope is well-positioned to further advance its innovative therapies and make significant contributions to the field of autoimmune disease treatment.